BioCentury

8:00 AM GMT, Dec 19, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical Results

Tasigna nilotinib: Phase III data

The open-label, international Phase III ENESTcmr trial in 207 patients showed that a non-significantly greater proportion of patients who switched to Tasigna achieved a confirmed CMR, the primary endpoint,

Read the full 290 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.